Table 3 Patient outcomes in unweighted, greedy-matching, and stabilized inverse probability of treatment–weighed samples

TSQM

Effectiveness

63.08 ± 13.75

62.40 ± 13.77

64.58 ± 13.64

 − 2.19 (− 5.06, 0.69)

62.27 ± 13.30

64.19 ± 13.32

 − 1.88 (− 5.23, 1.48)

62.09 ± 13.91

62.25 ± 12.69

 − 0.16 (− 3.25, 2.93)

Side effects^b, n (%)

356 (86.8)

241 (85.8)

115 (89.1)

 − 0.31 (− 0.96, 0.34)^a

115 (82.7)

82 (89.1)

 − 0.67 (− 0.15, 0.20)^a

93.95 ± 16.25

96.91 ± 11.44

 − 0.63 (− 1.42, 0.17) ^a

Convenience

67.95 ± 13.58

69.87 ± 13.37

63.76 ± 13.15

6.11 (3.34, 8.88)

68.79 ± 13.35

64.95 ± 12.85

3.84 (0.38, 7.30)

69.55 ± 13.62

63.96 ± 11.86

5.59 (2.66, 8.53)

Global satisfaction

58.24 ± 16.14

57.19 ± 16.46

60.52 ± 15.24

 − 3.33 (− 6.60, − 0.06)

56.68 ± 15.41

59.86 ± 15.56

 − 3.17 (− 7.18, 0.84)

57.04 ± 16.16

58.72 ± 14.68

 − 1.68 (− 5.26, 1.90)

EQ-VAS

65.42 ± 19.41

64.86 ± 19.63

66.78 ± 19.02

 − 1.92 (− 5.95, 2.11)

65.40 ± 19.97

65.67 ± 19.55

 − 0.27 (− 5.48, 4.95)

65.01 ± 19.18

67.59 ± 17.73

 − 2.58 (− 6.90, 1.73)

EQ-5D^c, n (%)

206 (50.5)

147 (52.3)

59 (46.5)

0.23 (− 0.18, 0.65)^a

72 (51.8)

41 (44.6)

0.31 (− 0.24, 0.87) ^a

0.81 ± 0.17

0.80 ± 0.14

0.24 (− 0.24, 0.72)^a